Loading...
Market
Bristol Myers meets CAR-T production target by 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Bristol Myers Squibb annual financial report or official press release.
Story
Bristol Myers, Cellares Ink $380M Deal to Boost CAR-T Therapy Production
Apr 22, 2024, 01:01 PM
Bristol Myers Squibb has signed a significant $380 million agreement with Cellares to enhance the production and supply of CAR-T cell therapies. This partnership aims to extend the reach of these therapies to more patients across the United States, European Union, and Japan. The deal involves Cellares acting as a contract manufacturer to help meet the growing demand for these innovative treatments.
View original story
Similar markets
Increase in sales • 33%
Decrease in sales • 33%
No significant change • 34%
Outperform • 33%
Underperform • 33%
Match • 33%
Bristol Myers Squibb • 25%
Gilead Sciences • 25%
Novartis • 25%
Other • 25%
$50 Billion • 25%
$60 Billion • 25%
$70 Billion • 25%
$80 Billion • 25%
Pre-clinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%